纳米颗粒中的金色化物Rb1/baicalein:一种潜在的纳米药物用于毒素菌治疗
Yingmei Lai1, Zhongao Zhang1, Xintian Yu1
1School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical college, Hangzhou 310013, PR China.
Acta tropica
|July 14, 2025
概括
基因化物Rb1基的纳米颗粒装有Baicalein (GRb1/BAI NPs) 为Toxoplasma gondii感染提供了一个有前途的新疗法,显示出增强的功效和安全性. 这些纳米粒子在体内有效减少寄生虫负担和囊,改善抗毒素菌的生存率.
科学领域:
- 纳米技术纳米技术
- 寄生虫学的寄生虫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 毒淋巴菌 (T. gondii) 是一种广泛传播的动物性寄生虫,引起了严重的公共卫生问题.
- 对T. gondii的现有治疗方法效果不佳,并产生不良副作用.
- 拜卡莱因 (BAI) 是一种天然化合物,表现出抗T. gondii的活性,但由于溶解性差和高毒性而受到限制.
研究的目的:
- 开发基因化物Rb1基纳米颗粒 (GRb1/BAI NPs),以克服治疗T. gondii感染的贝卡莱因的局限性.
- 评估GRb1/BAINP对毒素菌的物理化学特性,体外疗效和体内治疗效果.
主要方法:
- GRb1/BAI NPs是通过自组装合成的.
- 物理化学性质 (大小,泽塔潜力,封装效率,药物负载) 的特征.
- 在实验室中进行了细胞毒性和抗T. gondii增殖试验.
- 在急性和慢性毒素菌的小鼠模型中评估了体内疗效.
主要成果:
- GRb1/BAI NPs表现出有利的特性,包括最佳颗粒大小,稳定的泽塔潜力,高封装效率和持续释放.
- 与自由白卡林相比,GRb1/BAI NPs显示细胞毒性降低和抗T. gondii强度增强 (IC50从70.28微米减少到41.53微米).
- 在体内研究显示,寄生虫负担和脑囊显著减少,小鼠的生存时间延长,以及对急性和慢性毒素菌的保护作用.
结论:
- GRb1/BAI NPs代表了一种有前途的药物输送系统,用于增强贝卡莱因对T. gondii的治疗潜力.
- 使用天然辅助剂,如人参化物Rb1,为合成化合物提供了更安全的替代品,减轻了毒性风险.
- GRb1/BAI NPs显示出作为治疗毒素菌的新疗法药物的显著潜力.
更多相关视频
09:49Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay
Published on: April 29, 2020
7.2K
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
549
相关概念视频
01:28Toxoplasmosis
Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...